Carnegie Capital Asset Management LLC decreased its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 6.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,220 shares of the pharmaceutical company’s stock after selling 9,807 shares during the period. Carnegie Capital Asset Management LLC’s holdings in GlaxoSmithKline PLC were worth $5,632,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. FMR LLC raised its stake in GlaxoSmithKline PLC by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock valued at $1,079,047,000 after buying an additional 1,389,238 shares during the period. Fisher Asset Management LLC raised its stake in GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock valued at $540,483,000 after buying an additional 564,519 shares during the period. Renaissance Technologies LLC raised its stake in GlaxoSmithKline PLC by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock valued at $402,655,000 after buying an additional 4,935,900 shares during the period. Hotchkis & Wiley Capital Management LLC raised its stake in GlaxoSmithKline PLC by 4.3% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 7,847,327 shares of the pharmaceutical company’s stock valued at $338,377,000 after buying an additional 322,700 shares during the period. Finally, Bank of America Corp DE raised its stake in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock valued at $288,780,000 after buying an additional 934,928 shares during the period. Hedge funds and other institutional investors own 9.28% of the company’s stock.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded up 0.22% during midday trading on Thursday, reaching $40.48. The company had a trading volume of 1,162,055 shares. The company has a 50 day moving average price of $39.76 and a 200-day moving average price of $41.75. The firm has a market capitalization of $98.93 billion, a P/E ratio of 39.22 and a beta of 1.03. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be issued a dividend of $0.491 per share. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.86%. GlaxoSmithKline PLC’s payout ratio is presently 197.00%.

Several research firms have issued reports on GSK. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, September 21st. Citigroup Inc. lowered GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. BidaskClub lowered GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. TheStreet lowered GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Finally, ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the stock. GlaxoSmithKline PLC presently has a consensus rating of “Hold” and a consensus target price of $44.67.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/28/glaxosmithkline-plc-gsk-shares-sold-by-carnegie-capital-asset-management-llc.html.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related stocks with our FREE daily email newsletter.